Vitiligo, NB-UVB and tacrolimus: our experience in Naples

Area of Science:

• Dermatology
• Phototherapy
• Dermatological Treatments

Background:

• Vitiligo is a chronic autoimmune condition causing skin depigmentation.
• Current treatments aim to restore skin color and improve quality of life.
• Comparing established and novel therapeutic approaches is crucial for effective management.

Purpose of the Study:

• To compare the efficacy and safety of narrowband UVB (NB-UVB) phototherapy with tacrolimus ointment 0.1% for treating bilateral vitiligo.
• To evaluate repigmentation rates and impact on quality of life.

Main Methods:

• A randomized comparative study involving four groups of 12 patients with bilateral vitiligo.
• Patients received NB-UVB (311 nm) twice weekly and applied tacrolimus ointment 0.1% twice daily for 9 months.
• Clinical, photographic evaluations, and Dermatology Life Quality Index were used to assess outcomes.

Main Results:

• Partial repigmentation occurred in 71% of patients treated with tacrolimus ointment and 69% with NB-UVB after 36 weeks.
• Side effects were reported in a small percentage of patients in both groups.
• Dermatology Life Quality Index scores indicated comparable improvements.

Conclusions:

• NB-UVB phototherapy and tacrolimus ointment 0.1% demonstrate comparable efficacy in treating vitiligo.
• Tacrolimus ointment 0.1% is a suitable alternative treatment option for vitiligo patients.
• Further research may explore combination therapies for enhanced outcomes.